Sabra Health Care REIT, Inc. (SBRA) Stock Analysis and Metrics

Sector: Real Estate Industry: REIT - Healthcare Facilities CIK: 0001492298

P/E 33.64

ROIC (Qtr) 0.00

Total Debt (Qtr) 354.98 Mn

Add ratio to table...

About

Sabra Health Care REIT, Inc. operates as a self administered self managed real estate investment trust that acquires finances and owns healthcare real estate properties across the United States and Canada. The company leases these properties to third party operators or holds them under management agreements, providing housing and care services for seniors patients and individuals needing behavioral health or hospital care. Sabra generates revenue primarily from triple net lease payments on its owned properties where tenants cover taxes insurance...

Sabra Health Care REIT, Inc. operates as a self administered self managed real estate investment trust that acquires finances and owns healthcare real estate properties across the United States and Canada. The company leases these properties to third party operators or holds them under management agreements, providing housing and care services for seniors patients and individuals needing behavioral health or hospital care.

Sabra generates revenue primarily from triple net lease payments on its owned properties where tenants cover taxes insurance and maintenance. Additional income comes from management fees for senior housing communities operated by third parties, interest income on loans receivable, and dividends from preferred equity investments. The company's customers are healthcare operators including skilled nursing providers senior housing operators behavioral health providers and hospital operators.

Sabra Health Care REIT, Inc. organizes its operations into five reportable segments: Skilled Nursing/Transitional Care Senior Housing Leased Senior Housing Managed Behavioral Health and Specialty Hospitals and Other.

• This segment includes skilled nursing and transitional care facilities that provide nursing therapy rehabilitation medication management and daily living assistance to patients requiring short or long term care. The properties are leased under triple net agreements to operators who handle all operating expenses.

• This segment consists of independent living assisted living memory care and continuing care retirement communities that are leased to third party operators under triple net leases. Services range from housing and housekeeping to assistance with activities of daily living.

• This segment comprises senior housing communities operated by third party property managers under management agreements. The company retains exposure to operational performance while receiving management fees and avoids direct credit risk of the managers.

• This segment includes addiction treatment centers and behavioral hospitals that offer inpatient and outpatient care for substance abuse and mental health conditions. Properties are leased to operators who provide clinical services and the company receives lease income.

• This segment covers acute care long term acute care rehabilitation hospitals and other facilities such as residential services that are not classified elsewhere. These properties are leased to healthcare providers who deliver specialized medical services.

Sabra holds a mid size position within the healthcare REIT sector competing with larger peers such as Welltower Ventas and Healthpeak. Its competitive advantages stem from a geographically diversified portfolio a long weighted average lease term and strong relationships with a broad network of operators. The company also benefits from a disciplined capital allocation approach that emphasizes balance sheet strength and liquidity.

The company's tenants and operators are primarily skilled nursing facilities senior housing communities behavioral health centers and hospitals. No single tenant accounts for ten percent or more of total revenue indicating a diversified tenant base across the United States and Canada.

Investment thesis

Bull case

Sabra’s pipeline remains robust, with $240 million in awarded deals already in the pipeline for 2026, the vast majority of which target the self‑managed assisted living (SHOP) sector. The company’s guidance of 4.9–5.4 % NOI growth for SHOP, combined with a low‑to‑mid‑single‑digit escalation in Canadian RevPAR, signals that the firm is poised to capture significant pricing power as occupancy converges toward the high‑ninety percent range. The management team’s emphasis on operating leverage—particularly in acquisitions that start at 86–87 % occupancy—indicates a disciplined approach to maximizing incremental revenue while keeping incremental costs inflationary, which should lift cash NOI margins over time. The fact that Sabra has already transitioned four triple‑net facilities to the managed model, improving cash NOI by $1.3 million, demonstrates the scalability of its operating platform and the ability to convert passive assets into higher‑yielding operations without a proportional increase in capital expenditure. Their forward‑looking AT‑M equity issuance strategy, which has already raised over $322 million at attractive pricing, reflects a willingness to leverage equity markets to fund growth while keeping leverage at the target five‑times level, providing a cushion against potential interest rate spikes. The firm’s strong liquidity profile, with over $1.2 billion in available liquidity and a 5.00‑times debt to EBITDA ratio, ensures that the company can navigate any temporary supply‑side disruptions without compromising its long‑term acquisition cadence. Dividend consistency, with a quarterly payout of $0.30 per share fully covered by AFFO, signals confidence in cash flow generation and aligns management incentives with shareholder value creation. The recent focus on AI and business intelligence, coupled with a deep bench of ex‑operators, positions Sabra to fine‑tune occupancy strategies and operational efficiencies in real time, potentially delivering a higher return on invested capital than its peers. Finally, the Canadian market’s lower construction rate and higher occupancy trajectory provide a natural hedge against U.S. supply constraints, allowing the company to maintain or even accelerate growth in regions with the most favorable demand dynamics.
Sabra’s management consistently highlights the “robustness” of its deal pipeline and the high quality of its investment sourcing, yet it deliberately avoids disclosing specific deal valuations or projected IRR benchmarks beyond “low‑double‑digit” returns. This lack of transparency may obscure a potential shift toward lower‑yielding transactions that could erode long‑term profitability, especially if the competitive landscape intensifies. While the company projects a 5 % normalized AFFO growth, the underlying assumption that all newly acquired assets will quickly reach the same‑store performance thresholds may be overly optimistic, given the lag typically seen in transition assets and the uncertainty around the Canadian market’s ability to sustain its current pace of RevPAR expansion. The reliance on managed senior housing—an asset class that historically has experienced tighter margin compression during economic downturns—could expose the REIT to revenue volatility if demographic or macroeconomic shifts reduce demand for assisted living services. The company’s capital structure, though currently low‑leverage, has a high proportion of equity raised under AT‑M conditions, which may dilute existing shareholders if the market pricing remains favorable for a prolonged period. Despite the strong cash flow outlook, the firm's forward guidance does not account for potential rate cuts in Medicaid and Medicare reimbursements, which could diminish the operating income of its senior housing portfolio over the next few years. These factors collectively suggest that management’s bullish narrative may underestimate certain risks that could materialize and compress the firm’s upside.
The expansion into skilled nursing, while representing a small fraction of the current pipeline, signals a strategic diversification beyond SHOP. Management has repeatedly emphasized that skilled nursing investments are sourced from existing relationships, but they have provided no clarity on the performance metrics of these assets or how they will be integrated into the overall operational framework. If these properties underperform relative to the managed senior housing portfolio, the REIT’s operating model could become diluted, potentially weakening the perceived efficiency of its acquisition strategy. Additionally, the company’s commentary on regulated reimbursements—particularly the expected decline in Medicaid and Medicare rates—does not quantify the impact on the net operating income of these facilities, leaving investors uncertain about the long‑term viability of this asset class in the face of policy changes. The lack of detailed discussion about the capital allocation to new skilled nursing facilities, including potential higher cap rates or slower occupancy ramp, further obscures the strategic balance between higher‑yield SHOP and lower‑yield skilled nursing assets. Consequently, while the diversification strategy is presented as a growth lever, the risk of misallocation or underperformance remains unaddressed.
Sabra’s commitment to maintaining a 5‑times leverage target and its disciplined capital deployment strategy is reinforced by a 5.00‑times debt to EBITDA ratio at year‑end 2025. The company’s forward‑looking guidance assumes no significant disposition or capital markets activity beyond what is currently planned, but the real estate market’s cyclical nature could necessitate rapid divestiture or refinancing to preserve liquidity. Management’s description of the cash interest expense—$103 million at the midpoint—does not elaborate on the sensitivity of this expense to rising interest rates or potential refinancing costs if the firm needs to access the market under less favorable conditions. Moreover, while the company emphasizes ample liquidity, the reliance on a revolving credit facility (currently $782 million) exposes the firm to covenant risk if operational performance falters or if market conditions deteriorate, potentially constraining future investment capacity. The firm’s current dividend payout of 79 % of normalized AFFO is commendable, yet it also indicates a limited margin for reinvestment during periods of higher-than‑expected operating expenses or if acquisition costs rise due to intensified competition. These factors collectively underscore the importance of vigilant capital management and the potential fragility of the firm’s liquidity buffer in an adverse environment.
The company’s strategic focus on the Canadian market as a “lead” region for occupancy growth appears sound, but the firm’s commentary reveals an underlying uncertainty about the long‑term trajectory of RevPAR in the U.S. Management admits that Canadian facilities have achieved higher margins and occupancy, yet provides no concrete plan to replicate this success in the U.S. This gap could translate into a slower growth trajectory in the U.S., which currently represents the majority of Sabra’s portfolio. Furthermore, the firm’s acknowledgment of a higher construction rate in the U.S. relative to Canada introduces a supply constraint risk that could delay the ramp‑up of new assets, thereby impacting the projected NOI growth. In addition, the company’s operational model relies on close collaboration with operators, but it has not disclosed any formal partnership structures or incentive mechanisms that could align operator performance with the REIT’s financial objectives, potentially creating a misalignment of incentives. This lack of clarity on operational governance may expose the firm to execution risk, especially if operator performance declines or if the industry experiences a shift toward more aggressive service models that increase operating costs. Investors should therefore scrutinize the operational integration mechanisms and the potential impact on the company’s projected growth narrative.

Sabra’s pipeline remains robust, with $240 million in awarded deals already in the pipeline for 2026, the vast majority of which target the self‑managed assisted living (SHOP) sector. The company’s guidance of 4.9–5.4 % NOI growth for SHOP, combined with a low‑to‑mid‑single‑digit escalation in Canadian RevPAR, signals that the firm is poised to capture significant pricing power as occupancy converges toward the high‑ninety percent range. The management team’s emphasis on operating leverage—particularly in acquisitions that start at 86–87 % occupancy—indicates a disciplined approach to maximizing incremental revenue while keeping incremental costs inflationary, which should lift cash NOI margins over time. The fact that Sabra has already transitioned four triple‑net facilities to the managed model, improving cash NOI by $1.3 million, demonstrates the scalability of its operating platform and the ability to convert passive assets into higher‑yielding operations without a proportional increase in capital expenditure. Their forward‑looking AT‑M equity issuance strategy, which has already raised over $322 million at attractive pricing, reflects a willingness to leverage equity markets to fund growth while keeping leverage at the target five‑times level, providing a cushion against potential interest rate spikes. The firm’s strong liquidity profile, with over $1.2 billion in available liquidity and a 5.00‑times debt to EBITDA ratio, ensures that the company can navigate any temporary supply‑side disruptions without compromising its long‑term acquisition cadence. Dividend consistency, with a quarterly payout of $0.30 per share fully covered by AFFO, signals confidence in cash flow generation and aligns management incentives with shareholder value creation. The recent focus on AI and business intelligence, coupled with a deep bench of ex‑operators, positions Sabra to fine‑tune occupancy strategies and operational efficiencies in real time, potentially delivering a higher return on invested capital than its peers. Finally, the Canadian market’s lower construction rate and higher occupancy trajectory provide a natural hedge against U.S. supply constraints, allowing the company to maintain or even accelerate growth in regions with the most favorable demand dynamics.
Sabra’s management consistently highlights the “robustness” of its deal pipeline and the high quality of its investment sourcing, yet it deliberately avoids disclosing specific deal valuations or projected IRR benchmarks beyond “low‑double‑digit” returns. This lack of transparency may obscure a potential shift toward lower‑yielding transactions that could erode long‑term profitability, especially if the competitive landscape intensifies. While the company projects a 5 % normalized AFFO growth, the underlying assumption that all newly acquired assets will quickly reach the same‑store performance thresholds may be overly optimistic, given the lag typically seen in transition assets and the uncertainty around the Canadian market’s ability to sustain its current pace of RevPAR expansion. The reliance on managed senior housing—an asset class that historically has experienced tighter margin compression during economic downturns—could expose the REIT to revenue volatility if demographic or macroeconomic shifts reduce demand for assisted living services. The company’s capital structure, though currently low‑leverage, has a high proportion of equity raised under AT‑M conditions, which may dilute existing shareholders if the market pricing remains favorable for a prolonged period. Despite the strong cash flow outlook, the firm's forward guidance does not account for potential rate cuts in Medicaid and Medicare reimbursements, which could diminish the operating income of its senior housing portfolio over the next few years. These factors collectively suggest that management’s bullish narrative may underestimate certain risks that could materialize and compress the firm’s upside.
The expansion into skilled nursing, while representing a small fraction of the current pipeline, signals a strategic diversification beyond SHOP. Management has repeatedly emphasized that skilled nursing investments are sourced from existing relationships, but they have provided no clarity on the performance metrics of these assets or how they will be integrated into the overall operational framework. If these properties underperform relative to the managed senior housing portfolio, the REIT’s operating model could become diluted, potentially weakening the perceived efficiency of its acquisition strategy. Additionally, the company’s commentary on regulated reimbursements—particularly the expected decline in Medicaid and Medicare rates—does not quantify the impact on the net operating income of these facilities, leaving investors uncertain about the long‑term viability of this asset class in the face of policy changes. The lack of detailed discussion about the capital allocation to new skilled nursing facilities, including potential higher cap rates or slower occupancy ramp, further obscures the strategic balance between higher‑yield SHOP and lower‑yield skilled nursing assets. Consequently, while the diversification strategy is presented as a growth lever, the risk of misallocation or underperformance remains unaddressed.
Sabra’s commitment to maintaining a 5‑times leverage target and its disciplined capital deployment strategy is reinforced by a 5.00‑times debt to EBITDA ratio at year‑end 2025. The company’s forward‑looking guidance assumes no significant disposition or capital markets activity beyond what is currently planned, but the real estate market’s cyclical nature could necessitate rapid divestiture or refinancing to preserve liquidity. Management’s description of the cash interest expense—$103 million at the midpoint—does not elaborate on the sensitivity of this expense to rising interest rates or potential refinancing costs if the firm needs to access the market under less favorable conditions. Moreover, while the company emphasizes ample liquidity, the reliance on a revolving credit facility (currently $782 million) exposes the firm to covenant risk if operational performance falters or if market conditions deteriorate, potentially constraining future investment capacity. The firm’s current dividend payout of 79 % of normalized AFFO is commendable, yet it also indicates a limited margin for reinvestment during periods of higher-than‑expected operating expenses or if acquisition costs rise due to intensified competition. These factors collectively underscore the importance of vigilant capital management and the potential fragility of the firm’s liquidity buffer in an adverse environment.
The company’s strategic focus on the Canadian market as a “lead” region for occupancy growth appears sound, but the firm’s commentary reveals an underlying uncertainty about the long‑term trajectory of RevPAR in the U.S. Management admits that Canadian facilities have achieved higher margins and occupancy, yet provides no concrete plan to replicate this success in the U.S. This gap could translate into a slower growth trajectory in the U.S., which currently represents the majority of Sabra’s portfolio. Furthermore, the firm’s acknowledgment of a higher construction rate in the U.S. relative to Canada introduces a supply constraint risk that could delay the ramp‑up of new assets, thereby impacting the projected NOI growth. In addition, the company’s operational model relies on close collaboration with operators, but it has not disclosed any formal partnership structures or incentive mechanisms that could align operator performance with the REIT’s financial objectives, potentially creating a misalignment of incentives. This lack of clarity on operational governance may expose the firm to execution risk, especially if operator performance declines or if the industry experiences a shift toward more aggressive service models that increase operating costs. Investors should therefore scrutinize the operational integration mechanisms and the potential impact on the company’s projected growth narrative.

Bear case

Sabra’s growth narrative relies heavily on the assumption that its newly acquired SHOP assets will immediately or quickly reach the same‑store performance levels, yet the company’s own Q&A reveals that transition facilities remain a lagging subset of the portfolio. The management team has consistently avoided providing concrete timelines or quantitative metrics for how quickly these assets will hit target occupancy or NOI, creating an opaque area where the projected growth could stall. If these transition facilities underperform or take longer than anticipated, the firm’s overall NOI growth will be delayed, potentially pushing back the 2026 guidance and reducing the dividend payout capability. This uncertainty introduces a material risk that the market may not be adequately pricing into the stock.
While the company boasts a pipeline of $240 million in awarded deals, the majority of this pipeline is concentrated in the SHOP segment, with a small fraction allocated to skilled nursing. The company has repeatedly indicated that it sources skilled nursing opportunities from existing relationships, but it has provided no performance data or historical returns on those assets. Should these properties underperform or become subject to lower reimbursement rates, the diversification advantage the firm claims could evaporate, thereby increasing concentration risk in the SHOP portfolio and diminishing overall portfolio resilience. This risk is amplified by the firm's limited disclosure on how it will integrate and manage these properties within its operational framework.
The firm’s debt profile, while currently at a 5‑times leverage target, is heavily dependent on a revolving credit facility and forward equity issuance. Management’s forward‑looking guidance assumes no significant disposition or capital market activity beyond what is currently planned, but any sudden need for additional financing—stemming from a slower-than‑expected acquisition pace or higher interest costs—could force the firm to tap into the revolving line under unfavorable terms. Rising interest rates would increase the cost of borrowing, potentially eroding cash flow margins, while a dip in equity market conditions could force the firm to issue equity at a lower price, diluting existing shareholders. These scenarios are not fully incorporated into the company’s growth projections, thereby underestimating the financial flexibility risk.
Sabra’s guidance for 2026 presumes stable Medicaid and Medicare reimbursement rates, yet the company’s own commentary acknowledges that these rates are expected to decline gradually, returning to historical averages by 2026. Any acceleration in rate cuts or regulatory changes that impose stricter quality metrics could reduce net operating income for the senior housing portfolio. Furthermore, the firm’s discussion on regulatory outlooks is limited to high‑level statements, offering no quantitative stress testing of the impact on revenue streams. This lack of detail masks a potentially material downside that could materially erode profitability, especially if combined with a competitive pricing environment.
The company’s expansion into the Canadian market is framed as a growth lever, but the firm admits that RevPAR growth may be limited by the U.S. market’s higher construction rates and slower occupancy improvement. This disparity indicates that the firm’s growth potential in the U.S. could be constrained, leading to a slower-than‑anticipated NOI trajectory. Additionally, the firm’s acknowledgment of “cap rate compression” in the SHOP space, driven by an influx of private equity and other REITs, suggests that the firm may have to accept lower yields to close deals, thereby compressing its projected returns. These competitive pressures could erode the firm’s valuation multiple, especially if the market perceives that Sabra is no longer the dominant player in the sector.

Sabra’s growth narrative relies heavily on the assumption that its newly acquired SHOP assets will immediately or quickly reach the same‑store performance levels, yet the company’s own Q&A reveals that transition facilities remain a lagging subset of the portfolio. The management team has consistently avoided providing concrete timelines or quantitative metrics for how quickly these assets will hit target occupancy or NOI, creating an opaque area where the projected growth could stall. If these transition facilities underperform or take longer than anticipated, the firm’s overall NOI growth will be delayed, potentially pushing back the 2026 guidance and reducing the dividend payout capability. This uncertainty introduces a material risk that the market may not be adequately pricing into the stock.
While the company boasts a pipeline of $240 million in awarded deals, the majority of this pipeline is concentrated in the SHOP segment, with a small fraction allocated to skilled nursing. The company has repeatedly indicated that it sources skilled nursing opportunities from existing relationships, but it has provided no performance data or historical returns on those assets. Should these properties underperform or become subject to lower reimbursement rates, the diversification advantage the firm claims could evaporate, thereby increasing concentration risk in the SHOP portfolio and diminishing overall portfolio resilience. This risk is amplified by the firm's limited disclosure on how it will integrate and manage these properties within its operational framework.
The firm’s debt profile, while currently at a 5‑times leverage target, is heavily dependent on a revolving credit facility and forward equity issuance. Management’s forward‑looking guidance assumes no significant disposition or capital market activity beyond what is currently planned, but any sudden need for additional financing—stemming from a slower-than‑expected acquisition pace or higher interest costs—could force the firm to tap into the revolving line under unfavorable terms. Rising interest rates would increase the cost of borrowing, potentially eroding cash flow margins, while a dip in equity market conditions could force the firm to issue equity at a lower price, diluting existing shareholders. These scenarios are not fully incorporated into the company’s growth projections, thereby underestimating the financial flexibility risk.
Sabra’s guidance for 2026 presumes stable Medicaid and Medicare reimbursement rates, yet the company’s own commentary acknowledges that these rates are expected to decline gradually, returning to historical averages by 2026. Any acceleration in rate cuts or regulatory changes that impose stricter quality metrics could reduce net operating income for the senior housing portfolio. Furthermore, the firm’s discussion on regulatory outlooks is limited to high‑level statements, offering no quantitative stress testing of the impact on revenue streams. This lack of detail masks a potentially material downside that could materially erode profitability, especially if combined with a competitive pricing environment.
The company’s expansion into the Canadian market is framed as a growth lever, but the firm admits that RevPAR growth may be limited by the U.S. market’s higher construction rates and slower occupancy improvement. This disparity indicates that the firm’s growth potential in the U.S. could be constrained, leading to a slower-than‑anticipated NOI trajectory. Additionally, the firm’s acknowledgment of “cap rate compression” in the SHOP space, driven by an influx of private equity and other REITs, suggests that the firm may have to accept lower yields to close deals, thereby compressing its projected returns. These competitive pressures could erode the firm’s valuation multiple, especially if the market perceives that Sabra is no longer the dominant player in the sector.

Consolidation Items Breakdown of Revenue (2017)

Peer comparison

Companies in the REIT - Healthcare Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WELL	Welltower Inc.	152.39 Bn	103.20	14.42	-
2	VTR	Ventas, Inc.	42.85 Bn	160.69	6.99	-
3	DOC	Healthpeak Properties, Inc.	13.58 Bn	61.03	-30.38	6.78 Bn
4	OHI	Omega Healthcare Investors Inc	12.86 Bn	23.08	10.81	0.43 Bn
5	AHR	American Healthcare REIT, Inc.	9.58 Bn	88.14	4.11	0.96 Bn
6	CTRE	CareTrust REIT, Inc.	9.35 Bn	26.54	-102.15	0.50 Bn
7	HR	Healthcare Realty Trust Inc	7.08 Bn	-35.11	4.81	-
8	NHI	National Health Investors Inc	3.61 Bn	24.05	14.10	-

Research Tools

Developers

Sabra Health Care REIT, Inc. (NASDAQ: SBRA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2017)

Peer comparison

Research Tools

Developers

Sabra Health Care REIT, Inc. (NASDAQ: SBRA)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2017)

Peer comparison

Create an account

Sign In

Reset Password